Stocks · News reference

Why Is Armata Pharma Stock Gaining Monday?

Jul 20, 2026, 4:45 PMVandana Singh

ARMP stock jumps 10% as Armata Pharmaceuticals prepares its AP-SA02 multi-phage candidate for a pivotal Phase 3 trial in late 2026.

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Jul 20, 2026, 4:45 PM
Checked: Jul 20, 2026, 4:45 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 12, 2026, 8:29 PMBenzinga Newsdesk
Armata Pharmaceuticals Q2 EPS $(0.27) Beats $(0.45) Estimate, Sales $2.510M Beat $420.000K Estimate
Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.45) by 38.64 percent. This is a 40 percent increase over losses of $(0.45) per share
Read original at benzinga
ARMP
BenzingaAug 12, 2026, 8:14 PMBenzinga Newsdesk
Armata Pharmaceuticals Announces Promotion Of David House To CFO
Read original at benzinga
ARMP
BenzingaJul 20, 2026, 2:35 PMBenzinga Newsdesk
Armata Pharmaceuticals shares are trading higher after the company reported clinical, regulatory, manufacturing, and operational progress advancing AP‑SA02 toward a planned Phase 3 study in complicated Staphylococcus aureus bacteremia.
Read original at benzinga
ARMP